Growth Inhibition Activity Assessment of γ-Lactam-Containing Chemicals in Cultured MCF-7 Cells and Xenografted Chick...

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Breast cancer remains a significant health concern, necessitating the development of novel therapeutic agents.
• Gamma-butyrolactam (γ-lactam) derivatives represent a class of compounds with potential anticancer properties.
• Understanding the mechanisms of action and efficacy of these derivatives is crucial for drug development.

Purpose of the Study:

• To evaluate the growth-inhibitory effects of three γ-lactam derivatives (compounds 5, 6, and 8) on human breast cancer cells (MCF-7).
• To assess the in vivo efficacy and toxicity of these compounds using a chick embryo xenograft model.
• To investigate the potential involvement of EGFR and P53 signaling pathways in the observed effects.

Main Methods:

• In vitro assessment of growth inhibition using MTT assays and flow cytometry.
• Western blot analysis to determine the expression levels of cell cycle-associated proteins.
• In vivo evaluation using a chick embryo xenograft model to measure tumor growth inhibition.

Main Results:

• Compound 8 demonstrated significant growth inhibition of MCF-7 cells in vitro and reduced tumor size in the chick xenograft model (1.20 ± 0.37 mm vs. 1.97 ± 0.69 mm).
• Compound 8 exhibited relatively low toxicity compared to compounds 5 and 6.
• Western blot analysis indicated potential involvement of EGFR and P53 signaling pathways.

Conclusions:

• Compound 8 is a promising γ-lactam derivative with potent anti-breast cancer activity and favorable toxicity profile.
• The findings support further investigation of compound 8 as a potential therapeutic agent in mammalian models.
• EGFR and P53 signaling pathways may be key targets for compound 8's anticancer effects.